China Pharma Holdings (CPHI) Short term Debt (2013 - 2026)

China Pharma Holdings (CPHI) has reported Short term Debt for 14 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short term Debt rose 39.21% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (up 39.21% YoY), and the FY2025 full-year result was $2.0 million, up 72.69% from the prior year.
• Short term Debt climbed to $2.0 million in Q2 2026 per CPHI's latest filing, from $1.9 million in the prior quarter.
• Across five years, Short term Debt topped out at $4.3 million in Q1 2022 and bottomed at $1.0 million in Q3 2023.
• Historically, Short term Debt has averaged $2.0 million across 5 years, with a median of $1.9 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Short term Debt jumped 282.05% in 2022, then plunged 66.73% in 2023.
• Over 5 years, Short term Debt stood at $2.4 million in 2022, then slumped by 53.55% to $1.1 million in 2023, then rose by 0.99% to $1.1 million in 2024, then soared by 72.69% to $2.0 million in 2025, then decreased by 0.89% to $2.0 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $2.0 million, $1.9 million, and $2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.